ViRexx Medical Corp.

http://www.virexx.com

ViRexx Medical Corp. (ViRexx) is a development-stage biotechnology company focused on the development of therapeutic products for the treatment of certain cancers and specified chronic viral infections. The Company’s advanced programs include drug candidates for the treatment of chronic hepatitis B and C, selected solid tumors and liver cancer. The Company is engaged in conducting research and development in the areas of biopharmaceutical products on three technology platform: Targeted Autothrombogenic Cancer Therapy (T-ACT), Chimigen and OvaRex MAb. T-ACT platform is a tumour starvation technology platform. The Chimigen platform encompasses a molecular design recognizable by the body’s immune system to break tolerance by mounting a humoral (antibody), as well as a highly desirable cellular response to clear the virus that is responsible for the chronic infection. OvaRex MAb is a murine monoclonal antibody. (Source: ARS)

• 12/8/2013
• 5
• 0